Bonus Biogroup Ltd. (BBIXF)
Bonus Biogroup Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Haifa, HA, IL. The stock last traded at $0.08, up 0.00% on the session, giving a market capitalisation of $93.4M. On trailing twelve-month figures it carries a trailing P/E of -21.37, a net margin of 0.0%. Its beta of 0.79 implies it has historically moved less than the broad market.
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Bonus Biogroup Ltd. is most often compared with the following Healthcare names: